Prognostic factors of kidney cancer;Les facteurs pronostiques dans le cancer du rein

Progres en Urologie

Volumn 17, Issue 1 SUPPL. 1, 2007, Pages 139-143

  Patard, Jean Jacques ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INTERLEUKIN 2; TUMOR MARKER;

BIOLOGICAL MODEL; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MORTALITY; NEPHRECTOMY; PROGNOSIS; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; NEPHRECTOMY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447513942     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. NEGRIER S, ESCUDIER B, LASSET C, DOUILLARD JY, SAVARYJ, CHEVREAU C, RAVAUDA, MERCATELLO A, PENY J, MOUSSEAU M, PHILIP T, TURSZ T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-8.
2. NEGRIER S, ESCUDIER B, GOMEZ F, DOUILLARD JY, RAVAUD A, CHEVREAU C, BUCLON M, PEROL D, LASSET C. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunothérapie. Ann Oncol. 2002;13:1460-8
3. NEGRIER S, GOMEZ F, DOUILLARD JY, RAVAUD A, CHEVREAU C, BUCLON M, PEROL D, LASSET C, ESCUDIER B; Groupe Francais d'Immunotherapie. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol. 2005;23:161-5.
4. MOTZER RJ, BACIK J, MURPHY BA, RUSSO P, MAZUMDAR M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-96
5. MEKHAIL TM, ABOU-JAWDE RM, BOUMERHI G, MALHI S, WOOD L, ELSON P, BUKOWSKIR. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;2:832-41
6. PANTUCK AJ, ZISMAN A, BELLDEGRUN AS. Molecular markers for renal cell carcinoma. Rev Urol. 2000;2:171-2
7. ATKINS M, REGAN M, MCDERMOTT D.MIER J, STANBRIDGE E, YOUMANS A, FEBBO P, UPTON M, LECHPAMMER M, SIGNORETTIS. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005 May 15;11(10):3714-21
8. UPTON MP, PARKER RA, YOUMANS A, MCDERMOTT DF, ATKINS MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488-95
9. MOTZER RJ, MICHAELSON MD, REDMAN BG, HUDES GR, WILDING G, FIGLIN RA, GINSBERG MS, KIM ST, BAUM CM, DEPRIMO SE, LI JZ, BELLO CL, THEUER CP, GEORGE DJ, RINI BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24
10. RINI BI, JAEGER E, WEINBERG V, SEIN N, CHEW K, FONG K, SIMKO J, SMALL EJ, WALDMAN FM. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006;98:756-62
11. KATTAN MW, REUTER V, MOTZER RJ, KATZ J, RUSSO P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001 Jul;166(1):63-7
12. CINDOLO L, PATARD JJ, CHIODINIP, SCHIPS L, FICARRA V, TOSTAIN J, DE LA TAELLE A, ALTIERI V, LOBEL B, ZIGEUNER RE, ARTIBANIW, GUILLE F, ABBOU CC, SALZANO L, GALLO C. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer. 2005;104:1362-71
13. HUPERTAN V, ROUPRET M, POISSON JF, CHRETIEN Y, DUFOUR B, THIOUNN N, MEJEAN A. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer. 2006; 107:2604-8
14. FRANK I, BLUTE ML, CHEVILLE JC, LOHSE CM, WEAVERAL, ZINCKE H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-400
15. HCARRA V, MARTIGNONIG, LOHSE C, NOVARA G, PEA M, CAVALLERI S, ARTIBANI W. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol. 2006;175:1235-9
16. ZISMAN A, PANTUCK AJ, DOREY F, CHAO DH, GITLITZ BJ, MOLDAWER N, LAZAROVICID, DEKERNION JB, FIGLIN RA, BELLDEGRUN AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002;20:1368-74
17. PATARD JJ, KIMHL, LAM JS, DOREY FJ, PANTOCK AJ, ZISMAN A, FICARRA V, HAN KR, CINDOLO L, DE LA TAILLE A, TOSTAIN J, ARTIBANI W, DINNEY CP, WOOD CG, SWANSON DA, ABBOU CC, LOBEL B, MULDERS PF, CHOPIN DK, HGLIN RA, BELLDEGRUN AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22:3316-22
18. LAM JS, SHVARTS O, LEPPERT JT, HGLIN RA, BELLDEGRUN AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005; 173: 1853-62) (Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004 Aug 15;10:5464-71